Prime Medicine (PRME) Cash from Investing Activities (2021 - 2026)

Prime Medicine (PRME) has 6 years of Cash from Investing Activities data on file, last reported at $43.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 190.89% year-over-year to $43.4 million; the trailing twelve-month figure through Mar 2026 stood at -$17.6 million (down 130.53% YoY), and the FY2025 full-year result was -$108.8 million, down 258.88% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $43.4 million, up from $28.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $50.3 million in Q3 2024 and bottomed at -$92.1 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is $2.8 million (2025), against an average of -$1.5 million.
• The widest annual swing landed in 2023, when Cash from Investing Activities jumped 401.64%; it then tumbled 282.99% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$13.7 million in 2022, then surged by 401.64% to $41.3 million in 2023, then increased by 16.88% to $48.3 million in 2024, then sank by 41.29% to $28.3 million in 2025, then surged by 53.16% to $43.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $43.4 million (Q1 2026), $28.3 million (Q4 2025), and -$92.1 million (Q3 2025), per Business Quant data.

Peer Comparison